| Literature DB >> 35495713 |
Zhisheng Huang1,2, Hui Li2, Shuai Liu3, Ju Jia1,2, Ying Zheng2,4, Bin Cao1,2,4.
Abstract
Background: Influenza and COVID-19 are respiratory infectious diseases that are characterized by high contagiousness and high mutation and pose a serious threat to global health. After Influenza A virus (IAV) and SARS-CoV-2 infection, severe cases may develop into acute lung injury. Immune factors act as an important role during infection and inflammation. However, the molecular immune mechanisms still remain unclear. We aimed to explore immune-related host factors and core biomarker for severe infection, to provide a new therapeutic target of host factor in patients.Entities:
Keywords: IAV; Lipocalin 2; SARS-CoV-2; inflammatory response; severe infection
Year: 2022 PMID: 35495713 PMCID: PMC9039618 DOI: 10.3389/fmicb.2022.854172
Source DB: PubMed Journal: Front Microbiol ISSN: 1664-302X Impact factor: 5.640
FIGURE 1Immune landscape associated with IAV infection. Cellular subsets from CD45- (A) and CD45 + (B) cells in the lung (GSE107947). (C) Proportions of immune cells clusters in different studied subjects. (D) Top 20 upregulated genes of neutrophils at 48 hpi and MPS at 72 hpi. (E) Top eight GO terms of BP and MF in neutrophils. (F) Top eight GO terms of BP and MF in MPS. GSVA scores of response to virus (G) and inflammatory response (H) in different cell types.
FIGURE 2Identification and validation of key genes in IAV infection in public dataset. (A) Venn diagram to indicate 9 shared genes from DEGs and log2 fold change of shared genes (GSE107947). (B) Expression level of LCN2 in immune cells. (C) LCN2 expression level of neutrophils in different groups. (D,E) Validation of LCN2 in IAV infection.
FIGURE 3Correlation between LCN2 and clinical features of IAV infection in public dataset. (A) Expression level of LCN2 in healthy controls and patients with IAV infection (GSE111368). (B) Expression level of LCN2 in patients with mild, moderate, and severe influenza. (C) Expression level of LCN2 in acute and convalescent patients with IAV infection. (D) Association of patients’ age with expression level of LCN2. (E) Expression level of LCN2 in female and male patients with IAV infection.
FIGURE 4The association between LCN2 and disease severity in clinical patients with IAV infection. (A) Serum LCN2 levels in healthy controls and patients with IAV infection. (B,C) Serum LCN2 levels in patients with mild, moderate, and severe influenza. (D) Serum LCN2 levels in ARDS and non-ARDS patients with IAV infection.
FIGURE 5Functional analysis of LCN2 in patients with IAV. (A) DEGs between patients with low LCN2 and high LCN2 with IAV infection (GSE111368). (B) Heatmap of DEGs between patients with low LCN2 and high LCN2 with IAV infection. (C) GO terms and KEGG pathway enrichment analysis of DEGs between patients with low LCN2 and high LCN2 with IAV infection. (D) GSEA in groups with patients with high LCN2.
FIGURE 6The role of LCN2 in patients with COVID-19. (A) Expression level of LCN2 in ICU and non-ICU patients with COVID-19 (GSE157103). (B) Expression level of LCN2 in patients with COVID-19 with mechanical ventilation and without mechanical ventilation support. (C,D) Correlation analysis between LCN2 and SOFA, APACHE II in patients with COVID-19. (E) DEGs between patients with low LCN2 and high LCN2 with COVID-19. (F) Heatmap of DEGs between patients with low LCN2 and high LCN2 with COVID-19. (G) GO terms and KEGG pathway enrichment analysis of DEGs between patients with low LCN2 and high LCN2 with COVID-19.